European journal of gynaecological oncology (EUR J GYNAECOL ONCOL )

Journal description

Current impact factor: 0.60

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 0.602
2012 Impact Factor 0.577
2011 Impact Factor 0.474
2010 Impact Factor 0.633
2009 Impact Factor 0.614
2008 Impact Factor 0.641
2007 Impact Factor 0.587
2006 Impact Factor 0.652
2005 Impact Factor 0.591
2004 Impact Factor 0.509
2003 Impact Factor 0.547
2002 Impact Factor 0.395
2001 Impact Factor 0.562
2000 Impact Factor 0.551
1999 Impact Factor 0.397

Impact factor over time

Impact factor

Additional details

5-year impact 0.64
Cited half-life 7.10
Immediacy index 0.02
Eigenfactor 0.00
Article influence 0.16
Website European Journal of Gynaecological Oncology website
Other titles European journal of gynaecological oncology
ISSN 0392-2936
OCLC 7236962
Material type Periodical
Document type Journal / Magazine / Newspaper

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of study was review studies that have investigated the immune response in the presence of a malignant ovarian neoplasia. A review of the literature was performed to identify studies of malignant ovarian neoplasia, particularly studies that addressed the potential for cytokines, nitric oxide, and lymphocytes to mediate an immune response against ovarian cancer. Certain subsets of tumor-infiltrating leukocytes and/or tumor-associated leukocytes have been found to correlate with an improved disease prognosis, while other lymphocyte subsets (such as CD3+/CD4+/CD25+ T cells) have been associated with a poor diagnosis. These data suggest that cytokines can have a protective role, or can promote an immune system defense against a cancer. In particular, certain cytokines (e.g., IL 8, IL 10) represent attractive candidates for the development of new diagnostic, prognostic, and therapeutic strategies for the treatment of ovarian cancer. Keywords: Cytokines, nitric oxide, malignant ovarian neoplasia, cluster of differentiation, lymphocytes.
    European journal of gynaecological oncology 11/2014; 35(5):487-491.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Immunotherapies have been effective in treating various forms of cancer, including cervical intraepithelial neoplasias, predominantly caused by HPV. Development: To establish persistent infections in stratified epithelia, HPV induces proliferative lesions. Viral gene products are able to change gene expression and cellular proteins. The Interferons are inducible glycoproteins that have immunomodulatory, antiviral, antiproliferative and antiangiogenic effects. In particular, interferon- has been shown to inhibit the development and progression of cervical cancer. In this review, actions of interferons-α/β, including their receptors and signaling pathways, are described, as well as their clinical importance in the immune response against cervical lesions. Conclusion: The interaction of IFN-α/β with its receptor results in a series of phosphorylation events. These mechanisms can be ineffective in IFN response, then it can also compromise the therapeutic effects of immunotherapy.
    European journal of gynaecological oncology 08/2014; 35(4):368-372.
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE OF INVESTIGATION: To evaluate the distribution of GTPases RhoA, RhoB, and Cdc42 in cervical intraepithelial neoplasias (CIN) and invasive neoplasias of the uterine cervix. MATERIALS AND METHODS: samples of neoplastic lesions of the uterine cervix of 44 patients were classified in: CIN I (n = 10), CIN II (n = 10), CIN III (n = 09), and invasive carcinoma (n = 15). Antibodies anti-RhoA, anti-RhoB, and anti-Cdc42 were used and staining was classified as: negative, mild, moderate, and intense positive. RESULTS: When compared with dysplastic cells, superficial cells showed: higher expression of RhoB in CIN I (p = 0.0018), and lower expression of Cdc42 in CIN I (p = 0.0225). The authors observed higher expression of RhoA (p = 0.0002) and RhoB (p = 0.0046) in CIN dysplastic cells when compared with invasive carcinoma cells. CONCLUSIONS: GTPases Rho may be involved with the regulation of biological processes, important to the progression of cervical neoplasias. Probably, RhoA is important for maintenance of cell differentiation and RhoB protects cells from malignant cervical neoplasia.
    European journal of gynaecological oncology 07/2014; 35(3):284.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Within the last decades, the percentage of diagnosed cervical cancer in women of reproductive age has increased. The possibility of diagnosing small cervical tumors (< or = twocm) in childbearing age, can be explained due to the fact that many women, are aware of the benefits of Pap smear or colposcopy examination. Many demand a more conservative policy to handle such lesions in order to have an uneventful pregnancy in the near future.
    European journal of gynaecological oncology 01/2014; 35(4):373-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Choriocarcinoma is a highly malignant tumor of trophoblastic origin. Primary fallopian tube choriocarcinoma is an extremely rare occurrence, especially in women over 50 years of age. This article concerns a case of tubal choriocarcinoma developing in a 54-year-old woman, which the authors present together with a brief review of the literature. The woman presented with irregular vaginal bleeding for two months, following three months of amenorrhea. Transvaginal dopolar and pelvic computed tomography (CT) scan showed an adnexal cystomic-solid mass. Her serum human chorionic gonadotropin (hCG) levels were 29,1116 mIU/ml. The patient underwent hysterectomy and bisalpingo-oophorectomy. Histology was suggestive of tubal choriocarcinoma. Immunohistochemistry tests were positive for the hCG, Ki 67, CK, PLAP, and negative for CD30, supporting the diagnosis of choriocarcinoma. A combination of 5-Fu and KSM was administrated postoperatively. After four cycles of chemotherapy, her serum hCG level fell to the normal range. The patient remains disease-free 14 months after disease diagnosis.
    European journal of gynaecological oncology 01/2014; 35(5):604-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To explore the significance of combined detection of p53 genes and fragile histidine triad (FHIT) genes in cervical carcinoma.
    European journal of gynaecological oncology 01/2014; 35(3):298-300.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Carcinosarcoma is a rare, extremely aggressive tumor of the uterus with a poor prognosis. The authors describe a case of a 78-year-old woman who presented with a giant mass protruding through the cervix, vagina, and vulva. A total abdominal hysterectomy with bilateral salpingo-oophorectomy was performed. The histopathological examination of the surgical specimen revealed a malignant mixed Müllerian tumor. The clinical and pathological features, molecular data, and prognosis of this aggressive neoplasm are discussed. Although uterine carcinosarcomas are extremely rare, when a postmenopausal woman with a vulvar mass is admitted to the gynecology clinic, the physician should consider that the mass may be a carcinosarcoma.
    European journal of gynaecological oncology 01/2014; 35(4):458-60.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the mammography screening era, we experience increasing incidence of non-invasive lesions of the breast, particularly the ductal carcinoma in situ (DCIS). It is the authors' goal to better understand this disorder in order to be able to tailor therapy individually for each patient and, most of all, to avoid overtreatment. The authors analyzed all cases of DCIS diagnosed within one mammography screening unit between 2007 and 2013. Medical reports as well as a detailed case conference protocol were used to gain all required data. In a seven-year period, DCIS situ has been diagnosed 250 times in 249 women. Mostly the authors were able to obtain relevant information regarding tumor size, grade, biological characteristics, as well as surgery. This data was compared with current literature. Participating women who screen positive constitute a large patient sample. Thus, we have a large amount of clinical and histological information available for planning and conducting studies regarding DCIS as well as invasive breast cancer.
    European journal of gynaecological oncology 01/2014; 35(5):525-9.
  • European journal of gynaecological oncology 01/2014; 35(2):111-2.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clinical and histopathological factors that affect lymph node involvement in cervical cancer and the prognostic importance of these factors were evaluated in this study.
    European journal of gynaecological oncology 01/2014; 35(4):425-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: According to the National Health and Social Life Survey, sexual dysfunction affects about 43% of perimenopausal women. A diagnosis of cancer has a profound physical, emotional, and social impact, influencing the relationship with the body, the perception of illness and death, family, social and professional relationships, and the relationship with the partner and, consequently, sexuality. Loss of desire, dyspareunia, orgasmic disorder, difficulties in emotional and physical closeness to the partner, feelings of shame, and inadequacy commonly occur after treatment for uterine cancer; however, if these problems are associated with surgery or with radiotherapy, still remains unclear. According to this study, the authors may conclude that the experience of cancer could lead patients to a rediscovery of. their own sexuality and to an improvement in the relationship with their partner, showing that, sometimes, the relational and psychological factors assume greater importance than physical effects on sexuality, and they can somewhere compensate the morphofunctional failure.
    European journal of gynaecological oncology 01/2014; 35(6):662-5.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To identify factors affecting xenograft growth of epithelial ovarian cancer (EOC) cells in nude mice and to detect characteristic mutations occurring in the xenografts following serial passage.
    European journal of gynaecological oncology 01/2014; 35(4):387-92.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The analysis of acute and late toxicity of concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC) based on review of 120 patients treated in Centre of Oncology in Krakow between 2001 and 2007.
    European journal of gynaecological oncology 01/2014; 35(4):393-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The study was conducted to determine whether preoperative serum levels of cancer antigen (CA) 125, CA15- 3, CA19-9, carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP) are associated clinicopathologically with poor prognostic parameters and adjuvant treatment requirements in women with pure endometrioid endometrial cancer (EEC). The authors performed a retrospective review of EEC cases that were treated between January 2008 and January 2011. The association between preoperative tumor markers and prognostic parameters, recurrence risk, and adjuvant treatment requirements were investigated. Following univariate analyses, receiver-operating characteristic (ROC) curves were constructed for each marker to assess their capacity to predict prognostic parameters and need for adjuvant treatment. A total of 166 EEC cases were identified. Mean CA125, CA15-3, and CA19-9 levels were higher in cases that required adjuvant treatment (p < 0.05). CA125 had significant power for prediction of extrauterine disease, tumor size > two cm, lymphovascular space invasion (LVSI), deep myometrial invasion, cervical involvement, adnexal involvement, positive cytology, lymph node metastasis, and adjuvant treatment requirement. CA15-3 was a significant marker for adjuvant treatment prediction. CA19-9 could predict deep myometrial invasion, cervical involvement, and adjuvant treatment requirement. However, CEA and AFP did not have adequate capacity to predict any of the poor prognostic parameters and adjuvant treatment requirements. CONCLUSIONs: CA125 is currently one of the most important preoperative markers for identifying EEC cases that exhibit postoperatively poor prognostic pathologic findings and a consequent need for adjuvant treatment. CA15-3 and CA19- 9 were also significant markers with limited capacity in detecting prognostic parameters.
    European journal of gynaecological oncology 01/2014; 35(5):513-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Carbohydate antigen 125 (CA-125) is a type of cell surface glycoproteins present in more than 80% of non-mucinous epithelial ovarian carcinomas; however, benign gynecologic conditions commonly cause a smaller increase in CA-125 level. This report presents the details regarding a 44-year-old woman with extremely high serum CA-125 level and ascites. She complained of having abdominal pain and abdominal distension. Her serum CA-125 level had been markedly elevated (> 10,000 IU!ml) and computed tomograpgy (CT) revealed an ovarian tumor and massive ascites. The cytological analysis showed no evidence of malignancy, however, the positron emission CT (PET-CT) scan suggested ovarian malignancy with peritoneal carcinomatosis. Under the impression that the patient had ovarian cancer, the present surgical team carried out an explorative laparotomy and discovered the ruptured bilateral ovarian endometriomas. In this study, it is suggested that clinicians carrying out differential diagnosis of pelvic mass with high serum CA-125 level and ascites should consider not only ovarian cancer but also ruptured endometrioma.
    European journal of gynaecological oncology 01/2014; 35(4):469-72.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the relationship between ovarian volume and serum CA-125 levels.
    European journal of gynaecological oncology 01/2014; 35(3):280-3.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, the incidence of therapy-related myelodysplastic syndrome (t-MDS) and therapy-related acute myeloid leukemia (t-AML) that occur during chemotherapy for ovarian cancer has increased. While alkylating agents and topoisomerase II inhibitors are particularly mutagenic and have strong leukemogenic potential, paclitaxel and combination chemotherapy/radiation therapy also appear to induce t-MDS. The present authors report a case of t-MDS that developed during chemotherapy and radiation therapy for ovarian cancer. The patient was a 75-year-old woman who received six courses of cyclophosphamide/doxorubicin/cisplatin (CAP) therapy after initial surgery for Stage IIIc grade ovarian cancer in 1995. Beginning in February 2005, the patient experienced multiple recurrences due to sternal metastasis. Chemotherapy, including paclitaxel and carboplatin (TC), was administered intermittently and was combined with radiation therapy to a sternal metastatic lesion. Pancytopenia was observed in December 2008, and she was diagnosed with t-MDS (WHO subtype, refractory cytopenias with multilineage dysplasia [RCMD]): the time from first chemotherapy to t-MDS onset was 106 months. Without evidence of blast crisis, the recurrent lesions continued to grow and caused multiple cerebral infarctions, from which she eventually died. The cumulative doses of paclitaxel and carboplatin administered to this patient were 1,968 mg and 6,480 mg, respectively.
    European journal of gynaecological oncology 01/2014; 35(4):443-8.